Cargando…

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain and abnormal bowel patterns. Alteration in gut flora, visceral hypersensitivity, and abnormal bowel motility are among numerous factors in the complex pathophysiology of IBS. An...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iorio, Natalya, Malik, Zubair, Schey, Ron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467648/ https://www.ncbi.nlm.nih.gov/pubmed/26089696 http://dx.doi.org/10.2147/CEG.S67231

Ejemplares similares

Rifaximin Therapy of Irritable Bowel Syndrome
por: Koo, Hoonmo L., et al.
Publicado: (2012)

Lubiprostone for the Treatment of Adult Women with Irritable Bowel Syndrome with Constipation
por: Soubra, Mahmoud, et al.
Publicado: (2012)

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile
por: Gupta, Kamesh, et al.
Publicado: (2017)

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome
por: Jolley, John
Publicado: (2011)

Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Lembo, Anthony, et al.
Publicado: (2020)

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
por: Chey, William D., et al.
Publicado: (2020)

Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
por: Boltin, Doron, et al.
Publicado: (2014)

Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
por: Li, Jun, et al.
Publicado: (2016)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome
por: Zeber-Lubecka, Natalia, et al.
Publicado: (2016)

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
por: Pimentel, M., et al.
Publicado: (2017)

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome
por: Acosta, Andrés, et al.
Publicado: (2016)

Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Rezaie, Ali, et al.
Publicado: (2019)

Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
por: Bae, Suhyun, et al.
Publicado: (2015)

Acute Esophageal Necrosis Presenting With Henoch-Schönlein Purpura
por: Iorio, Natalya, et al.
Publicado: (2015)

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
por: Chang, Christopher
Publicado: (2018)

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
por: Soldi, Sara, et al.
Publicado: (2015)

Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?
por: Tocia, Cristina, et al.
Publicado: (2021)

Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Khan, Zarghuna, et al.
Publicado: (2023)

Irritable bowel syndrome: Is it “irritable brain” or “irritable bowel”?
por: Padhy, Susanta Kumar, et al.
Publicado: (2015)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Post-traumatic Stress Disorder Is Associated With Irritable Bowel Syndrome in African Americans
por: Iorio, Natalya, et al.
Publicado: (2014)

Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
por: Mangel, Allen W, et al.
Publicado: (2012)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin
por: DuPont, Herbert L., et al.
Publicado: (2016)

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2020)

Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity
por: Liu, Zuojing, et al.
Publicado: (2022)

Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation
por: Lee, Noel, et al.
Publicado: (2012)

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

Gut Microbiota as Potential Orchestrators of Irritable Bowel Syndrome
por: Bennet, Sean M.P., et al.
Publicado: (2015)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome
por: Vicari, Enzo, et al.
Publicado: (2017)

Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial
por: Cash, Brooks D., et al.
Publicado: (2017)

Diet in irritable bowel syndrome
por: El-Salhy, Magdy, et al.
Publicado: (2015)

The epidemiology of irritable bowel syndrome
por: Canavan, Caroline, et al.
Publicado: (2014)

Biomarkers of Irritable Bowel Syndrome
por: Kim, Jae Hak, et al.
Publicado: (2017)

Pharmacotherapy for Irritable Bowel Syndrome
por: Camilleri, Michael, et al.
Publicado: (2017)

Postinfection Irritable Bowel Syndrome
por: Ghoshal, Uday C
Publicado: (2022)

Irritable Bowel Syndrome and Resilience
por: Fadgyas Stanculete, Mihaela, et al.
Publicado: (2023)

Diagnosis of Irritable Bowel Syndrome: Role of Potential Biomarkers
por: Plavšić, Ivana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9v7m4v51p7lgkoehc9qbatqh6j